DUBLIN, June 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc JAZZ today announced that the company will be webcasting its corporate presentation at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA. 

Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update at the conference on Wednesday, June 13, 2018 at 9:20 a.m. PDT / 5:20 p.m. IST.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at http://www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at http://www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc JAZZ is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For country-specific product information, please visit http://www.jazzpharmaceuticals.com/products.  For more information, please visit http://www.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.

View original content with multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-at-the-goldman-sachs-global-healthcare-conference-300660711.html

SOURCE Jazz Pharmaceuticals plc